
Tapering strips are pre-packaged sets of daily medication doses that decrease in small, precise increments over weeks or months. They were developed in the Netherlands by a collaboration between the User Research Centre for Psychiatric Drugs and the compounding pharmacy Regenboog Apotheek, specifically to address a problem standard tablet strengths cannot solve: most antidepressants and benzodiazepines are not manufactured in the tiny doses required for a gradual withdrawal. Tapering strips explained in plain terms means a pharmacy makes the small doses for you, sealed in dated daily sachets, so you do not have to count beads, split tablets, or operate a milligram scale at your kitchen table. This article covers how tapering strips work, what the research shows, and why they have become a reference point in the broader conversation about safer deprescribing.
A tapering strip is a roll of small paper pouches, each labeled with a date and a precise dose. The pouches are connected like a strip of stamps, which is where the name comes from. Inside each pouch is a single day's worth of medication, compounded to an exact strength. As the strip progresses from day one to the final pouch, the dose drops in small steps, often as little as a fraction of a milligram per week.
A typical strip lasts 28 days and represents one stage of a longer plan. Someone tapering off Effexor might use a series of strips that move from 75 mg down to 1 mg over six to twelve months. The patient and prescriber decide the speed together, and the pharmacy compounds whatever schedule fits.
The doses follow a hyperbolic curve, meaning reductions get smaller as the total dose gets smaller. This matches the pharmacology of serotonergic and GABAergic drugs, where receptor occupancy does not drop linearly with dose. Cutting from 20 mg to 10 mg of an SSRI changes receptor occupancy far less than cutting from 5 mg to nothing. Hyperbolic tapering, first described in detail by Horowitz and Taylor in their 2019 Lancet Psychiatry paper, is the principle that makes tapering strips different from a standard prescriber-led taper using whole tablets.
The Dutch compounding pharmacy that produces most tapering strips works from a written request signed by the patient's prescriber. The prescriber specifies the drug, the starting dose, the end dose, and the duration. The pharmacy then calculates the daily increments and prepares the sachets, usually using powdered active ingredient mixed with a filler such as lactose or microcrystalline cellulose.
Each sachet is sealed, dated, and quality-checked. Because the medication is loose powder, the pharmacy can hit doses that branded tablets cannot, such as 0.4 mg, 0.7 mg, or 1.3 mg. This level of granularity is what makes tapering strips useful for the final weeks of a long taper, when the dose is small but the percentage change between days still matters.
The strips are shipped to the patient, sometimes internationally. In several European countries they are reimbursed by insurance. In the United Kingdom, United States, and Canada, patients typically pay out of pocket, and the cost varies based on the drug and the length of the taper. Some compounding pharmacies outside the Netherlands now offer similar pre-packaged tapers for Lexapro, Zoloft, Paxil, and a few benzodiazepines, though the Dutch operation remains the most studied.
The largest study on tapering strips is a 2018 observational paper by Groot and van Os published in Therapeutic Advances in Psychopharmacology. The researchers followed 895 patients who had previously failed to taper antidepressants using standard methods. Using tapering strips, 71 percent were able to come off their medication completely, and most reported withdrawal symptoms that were either mild or absent during the process.
A follow-up paper in 2020 extended this to over 1,200 patients with similar results. The authors noted that many participants had been on antidepressants for years, had tried and failed multiple tapers, and had developed a fear of withdrawal that itself complicated the process. The slow, predictable structure of the strips appeared to reduce both physical symptoms and anticipatory anxiety.
These studies are not randomized controlled trials, and the authors are transparent about that limitation. Critics have pointed out the absence of a comparator arm and the self-selected nature of the patient group. Supporters note that randomizing severe withdrawal cases to a method that has already failed them would be difficult to justify ethically. The Royal College of Psychiatrists in the UK updated its guidance on stopping antidepressants in 2019, partly in response to this body of evidence, and now recommends gradual hyperbolic tapering as the standard approach.
The patients who turn to tapering strips usually share a history. They have tried to stop their medication on the schedule their doctor suggested, often a few weeks of halving doses, and have experienced withdrawal symptoms severe enough to send them back on the drug. After one or two failed attempts, they begin searching online and discover that the standard advice does not match the experience reported by patient communities.
Long-term users of SSRIs, SNRIs, and benzodiazepines make up the bulk of the population using strips. People tapering Cymbalta, Effexor, and paroxetine are particularly common, because these drugs are known for severe discontinuation symptoms tied to their short half-lives and receptor binding profiles. Patients on Z-drugs and benzodiazepines also use compounded strips, often working from a longer half-life substitute under their prescriber's supervision.
The strips are not a magic solution. They require a willing prescriber, the ability to pay or get coverage, and the patience to follow a months-long protocol. Some patients still experience withdrawal, and a subset find they need to slow down further than the original strip schedule. The advantage is that slowing down is straightforward when the next dose is already a small, precise number rather than half of an unmarked tablet.
Patients who cannot access tapering strips often build their own version using one of several DIY methods. Liquid titration involves dissolving a tablet in a measured volume of water or using a manufacturer's oral solution, then drawing up shrinking doses with an oral syringe. Bead counting is used for capsules like Effexor XR that contain hundreds of small beads, where the patient empties a capsule and removes a small number of beads each week. Compounded capsules are individually made by a local compounding pharmacy at custom strengths.
Each DIY method introduces variables that tapering strips avoid. Liquid suspensions can settle, leading to inconsistent doses if not shaken thoroughly. Beads inside extended-release capsules are not always uniform in their contribution to the daily dose. Compounded capsules require a new prescription and a pharmacy visit at every step.
Tapering strips eliminate this work. The patient opens a pouch, takes the dose, and moves to the next pouch the next day. For people whose withdrawal symptoms include cognitive fog or anxiety, the absence of daily measurement decisions matters more than it sounds. The principle behind both approaches is the same, a slow hyperbolic reduction, but the execution differs in how much labor the patient carries.
Tapering strips are not available everywhere, and that is the largest practical limitation. Patients in the United States generally have to import them, which involves customs declarations, shipping delays, and no insurance coverage. The cost over a full taper can run into the hundreds or low thousands of dollars depending on the drug and duration.
The strips also work from a fixed schedule once printed. If a patient hits a difficult point and needs to hold the dose for several weeks, they have to either repeat days from earlier in the strip or order a hold strip. This is workable but adds friction. Some patient communities have argued that the schedule should be more responsive to symptoms in real time, similar to how a liquid taper allows for daily adjustment.
Finally, the underlying evidence still relies on observational data. A randomized trial comparing tapering strips to standard care has been discussed in the literature but has not been published at scale. Until that exists, the strips sit in a category of treatments that have strong patient-reported outcomes, biological plausibility, and growing clinical acceptance, but not the full evidence pyramid that regulators usually look for. The Maudsley Deprescribing Guidelines, published in 2024, treat hyperbolic tapering as the recommended framework and acknowledge tapering strips as one practical implementation of it.
Are tapering strips available in the United States? Not domestically as a single approved product. American patients usually order them from the Dutch pharmacy with a prescription, or work with a local compounding pharmacy to create a similar pre-packaged schedule. A growing number of US compounding pharmacies will produce sequential capsules at custom strengths if the prescriber writes a detailed taper plan.
How long does a typical taper take using strips? For antidepressants that have been used for more than a year, six to twelve months is common. Long-term benzodiazepine users often need a year or more. The duration depends on the starting dose, the drug's half-life, and the patient's response. Tapers that move too quickly tend to fail and require restarting from a higher dose.
Do I need a prescription? Yes. Tapering strips contain prescription medication and require a written request from a licensed prescriber. The pharmacy will not dispense without it. Some patients have to educate their prescriber about the option before getting the request signed.
What happens if I get severe symptoms during a strip? Most patients can hold at the current dose by repeating a sachet from earlier in the strip until symptoms settle, then resume. The prescriber and pharmacy can also issue a hold strip or a slower follow-up strip if the original pace is too fast. The strips are a starting point, not a contract.
Is hyperbolic tapering really better than linear tapering? The pharmacological case is strong. Receptor occupancy at low doses changes more steeply than at high doses, so equal milligram reductions create unequal biological effects. Clinical guidelines in the UK and Netherlands now recommend hyperbolic tapering for this reason, and the patient-reported outcome data, while observational, consistently favors the hyperbolic approach over linear taper schedules.
Tapering strips are one practical answer to a problem that has been ignored for decades: standard tablet strengths do not support the small, gradual reductions that long-term users of psychiatric medication often need. They are not the only answer, and they are not universally accessible, but they have shifted the conversation about what a careful taper looks like and what evidence should inform it.
If you are thinking about coming off antidepressants, benzodiazepines, or another psychiatric medication, the most important thing is not which method you choose but that you choose one and follow it with patience. Talking to people who have been through it helps. You can join the conversation at taper.community, where members share their schedules, their setbacks, and what worked for them.
Medical disclaimer: This article is for informational purposes only and is not medical advice. Do not start, stop, or change any medication without consulting your prescribing clinician. Withdrawal from psychiatric medications can be serious and should be managed with professional support.